Published in
Elsevier, The Lancet Oncology, 2(22), p. 159-160, 2021
DOI: 10.1016/s1470-2045(20)30757-9
Links
Tools
CDK4/6 inhibition in early-stage breast cancer: how far is it from becoming standard of care?
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 